Linperlisib plus chemoimmunotherapy for relapsed large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of large B-cell lymphoma (like DLBCL or high-grade B-cell lymphoma) that has come back or not responded to one prior treatment.
- You must have at least one tumor that can be measured on a scan.
- You must be at least 18 years old and be able to take care of yourself (ECOG 0-2).
- You cannot have had more than one line of cancer treatment before this trial.
- You cannot have had a stem cell transplant or a PI3K inhibitor drug before.
- You must not have active infections, autoimmune diseases, or serious heart/lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, BEBT-908, combined with rituximab for people with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment that included a CD20 antibody. The goal is to see if this new combination works better than standard care.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
This trial tests a combination of two drugs, linperlisib (a PI3K inhibitor) and rituximab, for people whose indolent (slow-growing) non-Hodgkin lymphoma has come back or stopped responding to treatment. It aims to see if adding linperlisib to rituximab can help shrink tumors.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests a combination of two oral drugs, chidamide and linperlisib, for people with follicular lymphoma that has not responded to or come back after at least two prior treatments. The goal is to see if this combination can help shrink the lymphoma and stop it from growing.
This trial tests whether adding the targeted drug linperlisib to standard chemotherapy (CHOP) can help adults with certain types of peripheral T-cell lymphoma that haven't been treated yet. It aims to see if the combination works better than CHOP alone.
Hear when a new Relapsed/Refractory Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.